Adaptogen Classification Criteria and What Qualifies a Plant

The word "adaptogen" gets slapped on everything from mushroom coffee to sleep gummies, but the term has an actual scientific definition with three specific criteria, and much of what gets sold under that label has not been rigorously tested against them. This piece walks through where the concept came from, what the criteria actually require, and which plants have earned the classification versus which ones borrowed it.

The origin of the word "adaptogen" and its original purpose

Nikolai Lazarev, a Soviet toxicologist, coined "adaptogen" in 1947. He wasn't looking for a wellness buzzword. He was searching for substances that could protect soldiers, factory workers, and pilots against an enormous range of physical stressors: radiation exposure, industrial chemical toxicity, extreme physical exertion, cold, psychological strain. The scope of the search explains why the resulting definition looks nothing like the marketing language attached to the word today.

Lazarev built directly on Hans Selye's general adaptation syndrome, the 1930s theory describing how the body responds to stress in stages regardless of the stressor's source. The Latin root, adaptare, means "to adjust or fit," and that's precisely what Lazarev was after: a substance that helped the body adjust to threat, generically, rather than treating one specific ailment. His first working definition centered on producing a "state of non-specific resistance" in the organism. Not sedation, not stimulation, just resilience that held up across categories of threat.

The Soviet research program that followed wasn't small. By 1982, over 1,000 studies had been conducted on botanicals like Schisandra chinensis and Eleutherococcus senticosus, examining their stress-protective properties. By 1982, over 1,000 studies had been conducted on botanicals like Schisandra chinensis and Eleutherococcus senticosus, examining their stress-protective properties, and this was treated as serious military and industrial science, backed by state research infrastructure, not folk remedy passed down through tradition.

The 1969 Brekhman–Dardymov paper and the three criteria that still govern classification today

Israel Brekhman and Igor Dardymov gave the concept its formal shape. Their 1969 paper is still cited in clinical reviews as the reference point for what qualifies a substance as an adaptogen, though the groundwork appears as early as 1967, when the pair began applying the term within pharmacognosy, describing adaptogens as innocuous medicinal plants capable of normalizing bodily functions in response to a range of harmful environmental conditions.

Three criteria came out of that work, and all three still have to be satisfied for a plant to earn the classification honestly.

The first is non-specificity. An adaptogen has to increase resistance across a broad range of stressors, physical, chemical, biological, rather than targeting one narrow threat. This is the criterion that separates adaptogens from conventional pharmaceuticals, which are typically built around a single mechanism aimed at a single problem.

The second is normalization, sometimes called bidirectionality. An adaptogen is supposed to nudge the body back toward homeostasis regardless of which direction it has drifted. If cortisol is running high, the substance should help bring it down. If the body is depleted and running low on energy, the same substance should help restore it. That's a strange property for a single compound to have, and it's the property that makes the classification so hard to test cleanly.

The third is non-toxicity. An adaptogen has to be safe at therapeutic doses, produce no tolerance or dependency, and remain safe under repeated, long-term use. This is what conceptually separates an adaptogen from a stimulant or a sedative, both of which can produce short-term relief but often at the cost of tolerance or withdrawal.

The HPA axis and cellular mechanisms behind the criteria

The primary physiological target for adaptogens is the hypothalamic-pituitary-adrenal axis, the three-station relay that governs the body's stress response. Signal moves from the hypothalamus to the pituitary gland to the adrenal glands, which then release cortisol. Adaptogens are understood to act on this axis by restoring its feedback sensitivity rather than suppressing the response. That distinction matters: a sedative dampens the alarm, while an adaptogen is theorized to recalibrate how sensitively the alarm goes off.

The autonomic nervous system functions as a secondary target. Adaptogens are described in the literature as pharmacologically pleiotropic, acting on multiple pathways within the neuroendocrine-immune system simultaneously. That pleiotropy is often used to explain why traditional medicine systems applied the same handful of herbs to such a wide array of complaints, fatigue, poor digestion, low immunity, disrupted sleep. One compound, many downstream effects, because the target system itself touches many downstream processes.

At the cellular level, one of the more specific mechanisms involves heat shock proteins. Rhodiola rosea and schisandra have both been shown to upregulate Hsp70, a molecular chaperone responsible for helping proteins fold correctly and clearing out proteins that have misfolded. Under chronic stress, misfolded protein buildup contributes to cellular fatigue and tissue wear over time. Inducing more Hsp70 activity effectively gives cells a larger buffer against that damage.

None of these three mechanisms, HPA axis recalibration, autonomic modulation, or heat shock protein induction, work by blunting the stress response. The body still responds to threat. What's being adjusted is closer to a volume knob than an off switch, and that recalibration is the biological expression of the normalization criterion described above.

Plants That Pass All Three Criteria

Screening plants through the three-criteria framework produces a fairly short list. The group most consistently referred to as "classical adaptogens" includes extracts from Panax ginseng, Eleutherococcus senticosus, Rhaponticum carthamoides, Rhodiola rosea, and Schisandra chinensis. These five have been studied specifically against the framework Brekhman and Dardymov laid out.

More than 110 medicinal plants have been reported to show some form of adaptogenic activity in the broader research literature. But only a handful genuinely comply with the most characteristic features of the three criteria, and the number of plants carrying the label has grown exponentially in recent years. That gap, between plants studied rigorously and plants simply called adaptogenic, is the core problem with how the term gets used commercially.

A useful way to sort the landscape is into two tiers. Primary adaptogens are those most consistently evaluated against all three criteria: ashwagandha (Withania somnifera), Rhodiola rosea, Panax ginseng, and schisandra rank among the most studied in this group, functioning as a benchmark against which newer claims are often measured.

Some plants show certain adaptogenic properties but also work through mechanisms that extend beyond the three-criteria framework, making a strict classification less clear-cut. These plants are not without merit, but their pharmacology does not map neatly onto what the original classification was built to describe.

Why "adaptogen" is not a regulated term

"Adaptogen" describes a pharmacological concept. It is not a regulatory category, and no drug authority anywhere certifies a plant or a product as belonging to this class. That absence of oversight is precisely what makes the term so easy to misuse.

In most countries, these botanicals sit on supplement shelves under far lighter scrutiny than pharmaceuticals face. Verifying whether a product actually contains what the label claims, in the amounts claimed, falls almost entirely on the person buying it.

The consequences of that gap aren't hypothetical. Between 2020 and 2023, the FDA issued a string of warning letters to supplement manufacturers making unapproved health claims for products marketed around adaptogens. Those letters are a documented record of the concept being stretched past what any regulator would allow a pharmaceutical company to claim, and they show the gap between the pharmacological concept and its regulatory reality isn't theoretical. It gets exploited.

Europe handles this with somewhat more structure. The European Medicines Agency's Committee on Herbal Medicinal Products has developed formal herbal monographs for established adaptogens like Panax ginseng, under Directive 2004/24/EC, laying out quality standards for products marketed under well-established or traditional use pathways. Even so, any manufacturer wanting to make a novel therapeutic claim beyond what's already established still needs full marketing authorization backed by clinical data. The monograph system covers tradition. It does not cover invention.

Legitimate scientific criticisms of the adaptogen concept itself

The three criteria sound clean on paper, but they run into real measurement problems once researchers try to test them.

"Non-specific resistance to stress" is a difficult thing to operationalize in a controlled trial. How do you design a study that measures resistance to categorically different stressors, chemical, physical, psychological, using one consistent outcome measure? The bidirectional normalization claim runs into the same wall, arguably worse. It's philosophically elegant to say a substance pushes cortisol down when it's high and up when it's low, but building a trial that confirms both directions simultaneously, in the same population, is scientifically awkward at best.

There's also a conceptual cost to lumping so many different molecular mechanisms under one label. Ginseng, rhodiola, and ashwagandha don't share a single pathway; grouping them together as "adaptogens" is a useful shorthand, but it can obscure the actual, distinct biochemistry driving each herb's effects when someone tries to understand how any one of them works on its own terms.

Even among people who prescribe these herbs professionally, there's no consensus on what the term means in daily practice. A focus group study involving naturopaths and Western herbalists found clinicians holding varied, sometimes conflicting interpretations of the adaptogenic concept. If practitioners who work with these plants regularly can't agree on what qualifies, the criteria clearly aren't being applied with much uniformity across the field.

And the exponential growth in the number of plants labeled adaptogenic, without matching growth in rigorous screening against the three criteria, has diluted the term's signal value. A label that once meant something specific and testable now gets attached to almost anything marketed for stress relief.

Using the three criteria as a practical filter when evaluating products and herbs

Faced with a product labeled "adaptogen," three questions do most of the filtering work. Does the evidence show resistance to multiple, distinct types of stressors, not just one narrow outcome measure? Is there human data showing a genuinely bidirectional or normalizing effect, rather than simple sedation or simple stimulation dressed up in adaptogen language? And is the substance documented as safe at therapeutic doses, with no signs of tolerance, dependency, or withdrawal on repeated use?

Classification is only step one, though. Extraction and preparation method determine how much of the plant's active material actually shows up in a usable form. Mushroom extracts are a clear example: dual-extraction methods, using both alcohol and water, pull out different bioactive fractions than a single-method extraction does. A herb can pass the three-criteria test in its studied form and still underdeliver in a poorly prepared product.

Dose ranges matter just as much as extraction method. Ashwagandha, for instance, is typically studied at 300 to 600 milligrams of standardized extract, taken twice daily. Products dosed well below or well above that range, or using non-standardized extracts with unclear potency, fall outside the evidence base that earned the herb its classification. The label on the bottle might say ashwagandha, but if the dose or extraction doesn't match what was studied, the clinical evidence doesn't transfer over automatically.

Cycling is worth a brief mention for herbs that interact directly with the HPA axis at sustained doses, ashwagandha being the clearest case. A pattern of roughly eight to twelve weeks on, followed by one to two weeks off, is a reasonable precaution given findings from 2025 on prolonged HPA-axis effects, even though no clinical guideline currently mandates that schedule. It's a hedge that's sensible given how directly these compounds interact with a feedback system the body relies on to regulate itself.